Lexston Life Sciences Corp. (LEXT.CN)
CAD 0.19
(18.75%)
CAD 0.19
(18.75%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | - | - | 361.01 Thousand | 149.11 Thousand | - |
| Cost of Revenue | 26.39 Thousand | 29.8 Thousand | 119.52 Thousand | 89 Thousand | - |
| Gross Profit | -26.39 Thousand | -29.8 Thousand | 241.48 Thousand | 60.1 Thousand | - |
| Operating Expenses | 674.71 Thousand | 871.53 Thousand | 2.1 Million | 551.18 Thousand | 6483.00 |
| Selling, General and Administrative Expenses | 674.71 Thousand | 871.53 Thousand | 1.94 Million | 496.72 Thousand | 6483.00 |
| Research and Development Expenses | - | 19.16 Thousand | 125.44 Thousand | 43.19 Thousand | - |
| Other Expenses | - | - | 31.98 Thousand | - | - |
| Cost and Expenses | 674.71 Thousand | 871.53 Thousand | 2.22 Million | 640.19 Thousand | 6483.00 |
| Operating Income | -674.71 Thousand | -871.53 Thousand | -1.86 Million | -106.04 Thousand | -6480.00 |
| Interest Expense | - | - | - | - | - |
| Income Tax Expense | - | 142.67 Thousand | 456.55 Thousand | 385.04 Thousand | -171.86 Thousand |
| Earnings before Tax | -734.28 Thousand | -966.06 Thousand | -2.32 Million | -876.13 Thousand | -6483.00 |
| Net Income | -867.71 Thousand | -1.1 Million | -2.32 Million | -876.13 Thousand | -6483.00 |
| Earnings Per Share Basic | -0.02 | -0.03 | -0.21 | -0.09 | -0.00 |
| Earnings Per Share Diluted | -0.03 | -0.04 | -0.21 | -0.09 | -0.00 |
| Weighted Average Shares Outstanding | 37.68 Million | 32.8 Million | 11.16 Million | 9.99 Million | 9.99 Million |
| Weighted Average Shares Outstanding (Diluted) | 31.89 Million | 28.58 Million | 11.16 Million | 9.99 Million | 9.99 Million |
| Gross Margin | - | - | 0.67 | 0.40 | - |
| EBIT Margin | - | - | -3.81 | -0.64 | - |
| Profit Margin | - | - | -6.43 | -5.88 | - |
| EBITDA | -648.32 Thousand | -841.73 Thousand | -1.88 Million | -479.81 Thousand | -6480.00 |
| Earnings Before Tax Margin | - | - | -5.16 | -0.71 | - |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | 6623.00 | 6574.00 | 6574.00 | 6623.00 | 29.8 Thousand |
| Gross Profit | - | -6623.00 | -6574.00 | -6574.00 | -6623.00 | -29.8 Thousand |
| Operating Expenses | 479.68 Thousand | 132.81 Thousand | 366.1 Thousand | 131.6 Thousand | 105.79 Thousand | 1.04 Million |
| Selling, General and Administrative Expenses | 307.91 Thousand | 85.37 Thousand | 366.1 Thousand | 99.35 Thousand | 72.61 Thousand | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 171.77 Thousand | 47.44 Thousand | - | - | - | - |
| Cost and Expenses | 479.68 Thousand | 113.04 Thousand | 372.67 Thousand | 138.17 Thousand | 112.41 Thousand | 1.07 Million |
| Operating Income | -479.68 Thousand | -113.04 Thousand | -372.68 Thousand | -138.17 Thousand | -112.41 Thousand | -1.07 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 18.64 Thousand | 133.43 Thousand | -4.00 | 2.00 | 1.00 | - |
| Earnings before Tax | -479.68 Thousand | -113.04 Thousand | -372.67 Thousand | -138.17 Thousand | -112.41 Thousand | -1.1 Million |
| Net Income | -498.33 Thousand | -246.47 Thousand | -372.67 Thousand | -138.17 Thousand | -112.41 Thousand | -1.1 Million |
| Earnings Per Share Basic | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | - |
| Earnings Per Share Diluted | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | - |
| Weighted Average Shares Outstanding | 44.26 Million | 32 Million | 32 Million | 30.31 Million | 30.3 Million | 28.58 Million |
| Weighted Average Shares Outstanding (Diluted) | 44.26 Million | 32 Million | 32 Million | 30.31 Million | 30.3 Million | 28.58 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -479.68 Thousand | -106.42 Thousand | -366.11 Thousand | -131.6 Thousand | -105.79 Thousand | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
002136
002935
IBM
ITB
RNMBY
VVU